Cambridge

Genzyme Europe Research is Genzyme’s first dedicated research and development facility in Europe based on the Cambridge Science Park in the UK.

The science team is currently focused on Antibody Technology. Additional complementary therapeutic technologies will be imported to increase the repertoire of the team as opportunities arise. The team is using phage display technology to create reagent antibodies for target validation purposes as well as candidate therapeutic antibodies to targets of interest. Both single chain variable domain (scFv) phage display libraries, as well as FAb phage libraries are being employed.

A close working relationship exists between the Cambridge Team and the Framingham (MA) based Molecular Immunology and New Protein Therapeutics Groups.

Targets of interest to the Oncology, IMD and Renal Biology Portfolios have been identified and efforts are underway to create single chain and FAb fragments to these targets. Following attainment of proof of concept in pre-clinical models, a major goal for the Cambridge team will be the use of Antibody Technology to create candidate therapeutic antibodies for use in clinical trials.

The Cambridge BMRA (Bio-Medical and Regulatory Affairs) group conduct global clinical trials, obtain regulatory approval for new medicines and perform all regulatory activities, for many countries. Therapeutic areas covered include Biosurgery, Oncology and Renal medicine.

Terms and Conditions of Use | Privacy Policy | © 2003-2008 Genzyme Corporation. All rights reserved.